The Dow Suffers Through Downward GDP Revisions as Merck, Pfizer Lead Decliners

Economic growth fears continued to be troublesome Tuesday, with the Dow's big pharma components helping to send the overall average lower.

May 6, 2014 at 12:31PM

The Dow Jones Industrials (DJINDICES:^DJI) was down 86 points as of 12:30 p.m. EDT. The most recent numbers on international trade as of March just came in; due to the differences between the Commerce Department's initial assumptions about trade data and the actual figures, many analysts reduced their estimates of final first-quarter U.S. GDP downward. With a range of -0.2% to -0.8% comparing unfavorably to the government's preliminary figure of +0.2%, the big question remains whether the economic hit was temporary due to the weather or symptomatic of longer-term issues. Leading the Dow downward this afternoon were Merck (NYSE:MRK) and Pfizer (NYSE:PFE), while energy stocks were relatively strong.

Mrk Vaccine

Source: Merck.

Merck dropped more than 2% after the drugmaker announced that it would sell its consumer drug division to Germany's Bayer for $14.2 billion in cash. The move is consistent with Merck's overall strategic direction in narrowing its scope to emphasize its prescription pharmaceutical division and vaccine production, which have been far more lucrative areas for the pharma industry and have much greater growth prospects. Shareholders should get roughly half of the proceeds from the sale in the form of stock buybacks, while Merck plans to spend the other half on research and development or on making acquisitions to bolster its pipeline prospects. Yet even though Merck also said that its MK-3475 advanced melanoma treatment received priority review designation, investors didn't respond favorably in the short term to the news, suggesting that shareholders want even more dramatic strategic moves in order to send the stock higher after good gains so far in 2014.


Pfizer fell 1.4% as the company continues to wrangle with its own merger and acquisition plans. So far, buyout target AstraZeneca has shown no signs of going down without a fight, with the British company arguing now that its long-term prospects are good and that shareholders should remain patient with the existing corporate structure rather than letting Pfizer reap the benefits with an opportunistic takeover bid. Pfizer shareholders initially liked the idea of a combination, but as it becomes clear that even a successful bid won't necessarily lead to a smooth transition, investors appear to be cooling to the idea. At this point, it's unclear what would persuade AstraZeneca to accept a bid, and that uncertainty isn't making Pfizer shareholders happy -- especially with so much in cost savings and tax benefits at stake.

Warren Buffett just bought nearly 9 million shares of this company
Imagine a company that rents a very specific and valuable piece of machinery for $41,000... per hour (that's almost as much as the average American makes in a year!). And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click HERE to discover more about this industry-leading stock... and join Buffett in his quest for a veritable landslide of profits!

Dan Caplinger and the Motley Fool have no position in the stocks mentioned in this article. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers